Vaccinex annual free cash flow
2017
2018
2019
2020
2021
2022
2023
2024
Vaccinex Free Cash Flow (FCF) History (VCNX)
Vaccinex reported −$16.2M in free cash flow for fiscal 2024, an increase of $5.2M from the previous fiscal year, with a free cash flow margin of −2696.84%.
View full Vaccinex company overviewVaccinex free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2024 | 2024-12-31 | −$16.2M | $5.2M | — | −2696.84% |
| 2023 | 2023-12-31 | −$21.4M | −$2.3M | — | −3762.46% |
| 2022 | 2022-12-31 | −$19.2M | $6.2M | — | −6972.00% |
| 2021 | 2021-12-31 | −$25.3M | $3.6M | — | −2814.44% |
| 2020 | 2020-12-31 | −$28.9M | $1.9M | — | −4629.92% |
| 2019 | 2019-12-31 | −$30.8M | −$5.3M | — | −5887.76% |
| 2018 | 2018-12-31 | −$25.5M | −$4.1M | — | −3523.62% |
| 2017 | 2017-12-31 | −$21.5M | — | — | −23838.89% |
Vaccinex quarterly free cash flow
Q3.17
Q1.18
Q2.18
Q3.18
Q4.18
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q3.21
Q3.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q4 2024 | 2024-12-31 | −$3.9M | $3.8M | — | −1846.01% |
| Q3 2024 | 2024-09-30 | −$3.2M | −$102,000 | — | −6182.69% |
| Q2 2024 | 2024-06-30 | −$4.4M | $1.1M | — | −1909.05% |
| Q1 2024 | 2024-03-31 | −$4.6M | $457,000 | — | −4453.85% |
| Q4 2023 | 2023-12-31 | −$7.7M | −$3.5M | — | — |
| Q3 2023 | 2023-09-30 | −$3.1M | $3.0M | — | −15565.00% |
| Q2 2023 | 2023-06-30 | −$5.5M | $876,000 | — | — |
| Q1 2023 | 2023-03-31 | −$5.1M | $4.3M | — | −925.27% |
| Q3 2022 | 2022-09-30 | −$4.2M | $1.3M | — | −8390.00% |
| Q3 2021 | 2021-09-30 | −$6.1M | $1.7M | — | −12138.00% |
| Q4 2020 | 2020-12-31 | −$6.4M | $4.1M | — | — |
| Q3 2020 | 2020-09-30 | −$9.3M | −$1.6M | — | −1495.04% |
| Q2 2020 | 2020-06-30 | −$5.4M | $1.8M | — | — |
| Q1 2020 | 2020-03-31 | −$7.8M | −$2.4M | — | — |
| Q3 2019 | 2019-09-30 | −$10.5M | −$5.3M | — | −2599.01% |
| Q4 2018 | 2018-12-31 | −$7.7M | −$3.0M | — | −3982.47% |
| Q3 2018 | 2018-09-30 | −$7.2M | — | — | −3648.99% |
| Q2 2018 | 2018-06-30 | −$5.3M | — | — | −4244.44% |
| Q1 2018 | 2018-03-31 | −$5.2M | — | — | −2530.10% |
| Q3 2017 | 2017-09-30 | −$4.7M | — | — | — |
Vaccinex free cash flow growth trends
Over the last five reported fiscal years, free cash flow grew from −$30.8M to −$16.2M, a net increase of $14.6M. Vaccinex's latest reported quarter, Q4 2024, generated −$3.9M in free cash flow, an increase of $3.8M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Vaccinex filings at SEC.gov ↗